NCT05525676 Relationship Checkups to Reduce Veteran Suicide Risk
| NCT ID | NCT05525676 |
| Status | Recruiting |
| Phase | — |
| Sponsor | VA Office of Research and Development |
| Condition | Relationship Distress |
| Study Type | INTERVENTIONAL |
| Enrollment | 360 participants |
| Start Date | 2023-01-03 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 360 participants in total. It began in 2023-01-03 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study compares two approaches to working with Veterans that have a mix of mental health and relationship concerns in primary care. One approach is a 3-session couple-based program called the Brief Relationship Checkup (BRC). BRC has shown promise improving relationship health in Air Force primary care (including some mental health symptoms related to relationship functioning) but has never been tested for individuals with significant mental health concerns. The other approach is a high-quality delivery of three sessions of Co-Located Collaborative Care (CCC) with the Screened Veteran only. This program is the current standard of care for Veterans reporting mental health concerns in primary care (including mental health concerns related to their relationship) but has never been tested for individuals struggling with relationship concerns. The goal is to compare the benefits of the couples-based program vs. the individual-based program when it comes to reducing suicide risk factors at the relationship level and the individual level.
Eligibility Criteria
Inclusion Criteria: 1. BOTH PARTNERS must be age 18 or over 2. BOTH PARTNERS must demonstrate sufficient knowledge of English and cognitive capacity to understand the study through comprehension of consent questions 3. BOTH PARTNERS must self-identify as "in a committed relationship" with their partner for at least 6-months. 4. AT LEAST ONE PARTNER must report at least mild relationship distress on a relationship satisfaction screen (CSI-4). 5. AT LEAST ONE PARTNER must be a VHA-enrolled Veteran who screens positive on a VA Primary Care Mental Health Screen for ONE OR MORE of the following conditions: Depressed Mood, Unsafe drinking, Posttraumatic stress, or Suicidal Ideation. Exclusion Criteria: 1. EITHER PARTNER reports that they are already engaged in ongoing couple or family therapy. 2. EITHER PARTNER reports severe intimate partner violence in the last year. 3. EITHER PARTNER reports ongoing or upcoming legal conflicts between one another (e.g., custody dispute; restraining order; divorce proceedings) 4. EITHER PARTNER reports experiencing suicidal intent requiring hospitalization. 5. EITHER PARTNER experiences past-month psychosis or mania. 6. EITHER PARTNER has completed therapy with the PI, Dr. Dev Crasta, within the last 5 years.
Contact & Investigator
Dev J Crasta
PRINCIPAL INVESTIGATOR
VA Finger Lakes Healthcare System, Canandaigua, NY
Frequently Asked Questions
Who can join the NCT05525676 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Relationship Distress. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05525676 currently recruiting?
Yes, NCT05525676 is actively recruiting participants. Contact the research team at Jovana.Demonjic@va.gov for enrollment information.
Where is the NCT05525676 trial being conducted?
This trial is being conducted at Canandaigua, United States.
Who is sponsoring the NCT05525676 clinical trial?
NCT05525676 is sponsored by VA Office of Research and Development. The principal investigator is Dev J Crasta at VA Finger Lakes Healthcare System, Canandaigua, NY. The trial plans to enroll 360 participants.